{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:29:21Z","timestamp":1786980561529,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,6,29]],"date-time":"2018-06-29T00:00:00Z","timestamp":1530230400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s10147-018-1310-7","type":"journal-article","created":{"date-parts":[[2018,6,29]],"date-time":"2018-06-29T10:55:08Z","timestamp":1530269708000},"page":"1127-1133","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Radiotherapy combined with zoledronate can reduce skeletal-related events in renal cell carcinoma patients with bone metastasis"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9820-5375","authenticated-orcid":false,"given":"Seiichi","family":"Hosaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohisa","family":"Katagiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Niwakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Wasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,29]]},"reference":[{"key":"1310_CR1","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1093\/jjco\/hyv088","volume":"45","author":"M Hori","year":"2015","unstructured":"Hori M, Matsuda T, Shibata A et al (2015) Cancer incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol 45:884\u2013891","journal-title":"Jpn J Clin Oncol"},{"key":"1310_CR2","first-page":"7","volume-title":"Management of metastatic bone disease","author":"KD Harrington","year":"1988","unstructured":"Harrington KD (1988) Management of metastatic bone disease. The CV Mosby Company, St. Louis, pp\u00a07\u201317"},{"key":"1310_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/0470011610","volume-title":"Textbook of bone metastases","author":"C Jasmin","year":"2005","unstructured":"Jasmin C, Capanna R, Coia L et al (2005) Textbook of bone metastases. Wiley, New Jersey"},{"key":"1310_CR4","first-page":"379","volume":"19","author":"J Zekri","year":"2001","unstructured":"Zekri J, Ahmed N, Coleman RE et al (2001) The skeletal complications of renal cell carcinoma. Int J Oncol 19:379\u2013382","journal-title":"Int J Oncol"},{"key":"1310_CR5","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/j.1464-410X.2008.08124.x","volume":"103","author":"T Kijima","year":"2008","unstructured":"Kijima T, Fujii Y, Suyama T et al (2008) Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronete. Br J Urol Int 103:620\u2013624","journal-title":"Br J Urol Int"},{"key":"1310_CR6","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/1097-0142(19830215)51:4<614::AID-CNCR2820510411>3.0.CO;2-J","volume":"51","author":"EC Halperin","year":"1983","unstructured":"Halperin EC, Harisiadis L (1983) The role of radiation therapy in the management of metastatic renal cell carcinoma. Cancer 51:614\u2013617","journal-title":"Cancer"},{"key":"1310_CR7","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.ijrobp.2009.10.056","volume":"79","author":"M Mizumoto","year":"2009","unstructured":"Mizumoto M, Harada H, Asakura H et al (2009) Radiotherapy for patients with metastases to the spinal column: a review of 603 patients at Shizuoka Cancer Center Hospital. Int J Rad Oncol Biol Phys 79:208\u2013213","journal-title":"Int J Rad Oncol Biol Phys"},{"key":"1310_CR8","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/01.blo.0000149820.65137.b4","volume":"431","author":"B Fuchs","year":"2005","unstructured":"Fuchs B, Trousdale RT, Rock MG (2005) Solitary bone metastasis from renal cell carcinoma. Clin Orthop Relat Res 431:187\u2013192","journal-title":"Clin Orthop Relat Res"},{"key":"1310_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/annonc\/mdm411","volume":"18","author":"S Oudard","year":"2007","unstructured":"Oudard S, George D, Medioni J et al (2007) Treatment options in renal cell carcinoma; past, present and future. Ann Oncol 18:25\u201331","journal-title":"Ann Oncol"},{"key":"1310_CR10","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","volume":"27","author":"RJ Motzer","year":"2009","unstructured":"Motzer RJ, Hutson TE, Tomczak P et al (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584\u20133590","journal-title":"J Clin Oncol"},{"key":"1310_CR11","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1093\/annonc\/mdq554","volume":"22","author":"B Beuselinck","year":"2011","unstructured":"Beuselinck B, Oudard S, Rixe O et al (2011) Negative impact of bone metastasis on outcome in clear-cell renal carcinoma treated with sunitinib. Ann Oncol 22:794\u2013800","journal-title":"Ann Oncol"},{"key":"1310_CR12","first-page":"377","volume":"7","author":"LS Rosen","year":"2001","unstructured":"Rosen LS, Gordon D, Kaminski M et al (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: phase III, double-blind, comparative trial. Cancer J 7:377\u2013387","journal-title":"Cancer J"},{"key":"1310_CR13","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","volume":"21","author":"LS Rosen","year":"2003","unstructured":"Rosen LS, Gordon D, Tchekmedyian S et al (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: phase III, double-blind, randomized trial the zoledronic acid lung cancer and the other solid tumors study group. J Clin Oncol 21:3150\u20133157","journal-title":"J Clin Oncol"},{"key":"1310_CR14","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1111\/j.1464-410X.2005.05740.x","volume":"96","author":"F Saad","year":"2005","unstructured":"Saad F, Lipton A (2005) Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers. Br J Urol Int 96:964\u2013969","journal-title":"Br J Urol Int"},{"key":"1310_CR15","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1269\/jrr.09096","volume":"51","author":"H Harada","year":"2010","unstructured":"Harada H, Katagiri H, Kamata M et al (2010) Radiological response and clinical outcome in patients with femoral bone metastases after radiotherapy. J Radiat Res 51:131\u2013136","journal-title":"J Radiat Res"},{"key":"1310_CR16","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1002\/cam4.292","volume":"3","author":"H Katagiri","year":"2014","unstructured":"Katagiri H, Okada R, Takagi T et al (2014) New prognostic factors and scoring system for patients with skeletal metastasis. Cancer Med 3:1359\u20131367","journal-title":"Cancer Med"},{"key":"1310_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1471-2407-13-3","volume":"13","author":"T Yuasa","year":"2013","unstructured":"Yuasa T, Kitsukawa S, Sukegawa G et al (2013) Early onset recall pneumonitis during targeted therapy with sunitinib. BMC Cancer 13:3","journal-title":"BMC Cancer"},{"key":"1310_CR18","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.jcma.2016.01.008","volume":"79","author":"CL Chiang","year":"2016","unstructured":"Chiang CL, Chen YW, Wu MH et al (2016) Radiation recall pneumonitis induced by epidermal growth factor receptor-tyrosine kinase inhibitor in patients with advanced non-small-cell lung cancer. J Chin Med Assoc 79:248\u2013255","journal-title":"J Chin Med Assoc"},{"key":"1310_CR19","unstructured":"Norick AC, Retik AB et al (2002) Renal tumors. In: Campbells urology 8th edn. W. B. Saunders Co., Philaderphia, pp\u00a02685\u20132703"},{"key":"1310_CR20","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1200\/JCO.2008.19.5511","volume":"27","author":"B Escudier","year":"2009","unstructured":"Escudier B, EiseEn T, Stadler WM et al (2009) Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27:3312\u20133318","journal-title":"J Clin Oncol"},{"key":"1310_CR21","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ejca.2011.11.027","volume":"48","author":"E Calvo","year":"2012","unstructured":"Calvo E, Escudier B, Motzer RJ et al (2012) Everolimus in metastatic renal cell carcinoma: subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Can 48:333\u2013339","journal-title":"Eur J Can"},{"key":"1310_CR22","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00432-009-0664-7","volume":"136","author":"J \u017bo\u0142nierek","year":"2010","unstructured":"\u017bo\u0142nierek J, Nurzy\u0144ski P, Langiewicz P et al (2010) Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases. J Cancer Res Clin Oncol 136:371\u2013378","journal-title":"J Cancer Res Clin Oncol"},{"key":"1310_CR23","first-page":"2940","volume":"63","author":"KL Weber","year":"2003","unstructured":"Weber KL, Doucet M, Price JE et al (2003) Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice. Cancer Res 63:2940\u20132947","journal-title":"Cancer Res"},{"key":"1310_CR24","first-page":"327","volume":"9","author":"DB Mendel","year":"2003","unstructured":"Mendel DB, Laird AD, Xin X et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship. Clin Cancer Res 9:327\u2013337","journal-title":"Clin Cancer Res"},{"key":"1310_CR25","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/j.1442-2042.2010.02468.x","volume":"17","author":"A Yokomizo","year":"2010","unstructured":"Yokomizo A, Koga H, Shinohara N et al (2010) Skeletal-related events in urological cancer patients with bone metastasis: a multicenter study in Japan. Int J Urol 17:332\u2013336","journal-title":"Int J Urol"},{"key":"1310_CR26","doi-asserted-by":"publisher","first-page":"9443","DOI":"10.1158\/0008-5472.CAN-07-1473","volume":"67","author":"JP Plastaras","year":"2007","unstructured":"Plastaras JP, Kim SH, Liu YY et al (2007) Cell cycle-dependent and schedule-dependent antitumour effects of sorafenib combined with radiation. Cancer Res 67:9443\u20139454","journal-title":"Cancer Res"},{"key":"1310_CR27","first-page":"4599","volume":"16","author":"D Taussky","year":"2009","unstructured":"Taussky D, Souli\u00e8res D (2009) Hypofractioned radiotherapy with concomitant sunitinib\u2014is there a radiosensitizing effect? Can J Urol 16:4599\u20134600","journal-title":"Can J Urol"},{"key":"1310_CR28","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1093\/annonc\/mdq554","volume":"22","author":"B Beuselinck","year":"2011","unstructured":"Beuselinck B, Oudard S, Rixe O et al (2011) Negative impact of bone metastasis on outcome in clear-cell carcinoma treated with sunitinib. Ann Oncol 22:794\u2013800","journal-title":"Ann Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-018-1310-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-018-1310-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-018-1310-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T19:20:26Z","timestamp":1561749626000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-018-1310-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,29]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1310"],"URL":"https:\/\/doi.org\/10.1007\/s10147-018-1310-7","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,29]]},"assertion":[{"value":"1 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}